Private company

Surface Oncology, Inc.

American biological products company based in Cambridge, no longer active. Summary from the record

Last updated Oct 19, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersCambridge, United States2
  • Incorporated inDE3
  • Business address50 Hampshire Street, 8Th Floor, Cambridge, Ma 021393
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI549300FCSG6MNIMFH7382
  • StatusInactive2
  • LEI statusRetired2
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 55247492

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-206.2%Operating margin4
-212.0%Net margin4
1016.5%Revenue growth, 20224
-68.1%Return on equity4
-$60.0MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development96¢$67.0M
  • Interest4¢$3.1M

Out of $30.0M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$30.0M in 2022+352% since 2016
0$25.0M$50.0M$75.0M$100.0M2016: $6.6M$6.6M20162017: $12.8M$12.8M2017+93%2018: $0$020182019: $0$020192020: $87.6M$87.6M20202021: $2.7M$2.7M2021−97%2022: $30.0M$30.0M2022+1016%
Operating income56784-$61.9M in 2022+244% since 2016
-$100.0M-$50.0M0$50.0M$100.0M2016: -$18.0M-$18.0M20162017: -$46.0M-$46.0M2017+155%2018: -$9.2M-$9.2M2018−80%2019: -$57.4M-$57.4M2019+527%2020: $61.6M$61.6M20202021: -$76.0M-$76.0M20212022: -$61.9M-$61.9M2022−19%
Net income56784-$63.6M in 2022+264% since 2016
-$100.0M-$50.0M0$50.0M$100.0M2016: -$17.5M-$17.5M20162017: -$45.4M-$45.4M2017+160%2018: -$6.6M-$6.6M2018−85%2019: -$54.8M-$54.8M2019+731%2020: $59.3M$59.3M20202021: -$78.5M-$78.5M20212022: -$63.6M-$63.6M2022−19%
Fiscal year2016201720182019202020212022
Revenue$6.6M5$12.8M6$07$08$87.6M4$2.7M4$30.0M4
Research and development$20.5M5$47.8M6$52.5M7$52.1M8$41.0M4$53.6M4$67.0M4
Operating expenses$78.7M4$91.9M4
Operating income-$18.0M5-$46.0M6-$9.2M7-$57.4M8$61.6M4-$76.0M4-$61.9M4
Interest$145.0K8$2.9M4$2.5M4$3.1M4
Income before tax-$78.5M4-$63.6M4
Net income-$17.5M5-$45.4M6-$6.6M7-$54.8M8$59.3M4-$78.5M4-$63.6M4
Earnings per share-$0.337-$1.978$1.674-$1.774-$1.144
Earnings per share (diluted)-$0.337-$1.978$1.574-$1.774-$1.144
Shares (weighted, basic)44.2M shares455.8M shares4
Shares (weighted, diluted)44.2M shares455.8M shares4

Compare Surface Oncology, Inc. with another company

Leadership

Who has led Surface Oncology, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jeff Goater2018–2021

Chief financial officer

  1. Jessica Fees2022–2023
20202025
Board members and other officers (19)

Timeline

  1. Apr 18, 2018New chief executive Jeff Goater becomes CEO11
  2. Apr 29, 2014Founded Surface Oncology, Inc. is founded2

Filings

122 filings to the SEC since October 2021: 3 annual reports, 6 quarterly reports, 21 major events, 52 insider forms, 9 large holders, 31 other. The latest 20:

  1. Sep 18, 202315-12G EDGAR
  2. Sep 12, 2023EFFECT EDGAR
  3. Sep 12, 2023EFFECT EDGAR
  4. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  5. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  6. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  7. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  8. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  9. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  10. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  11. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  12. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  13. Sep 8, 2023S-8 POS EDGAR
  14. Sep 8, 2023S-8 POS EDGAR
  15. Sep 8, 2023S-8 POS EDGAR
  16. Sep 8, 2023S-8 POS EDGAR
  17. Sep 8, 2023S-8 POS EDGAR
  18. Sep 8, 2023S-8 POS EDGAR
  19. Sep 8, 2023POS AM EDGAR
  20. Sep 8, 2023POS AM EDGAR

The 122 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

9 open-market trades by officers, directors and large owners since October 2021: 0 buys and 9 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 1, 2023ONEILL ALISONChief Medical OfficerSale7,042$0.94$6.6KForm 4
Aug 1, 2023Adams ChandraDeputy GCSale3,901$0.94$3.7KForm 4
Aug 1, 2023FEES JESSICAChief Financial OfficerSale9,434$0.94$8.9KForm 4
Aug 1, 2023ROSS ROBERT W.Chief Executive OfficerSale16,713$0.94$15.7KForm 4
Aug 3, 2022RATH HENRY C.Chief Business OfficerSale5,676$1.72$9.8KForm 4
Aug 3, 2022ONEILL ALISONChief Medical OfficerSale4,463$1.72$7.7KForm 4
Aug 3, 2022ROSS ROBERT W.Chief Executive OfficerSale10,594$1.72$18.2KForm 4
Aug 3, 2022FEES JESSICAChief Financial OfficerSale5,980$1.72$10.3KForm 4
Aug 3, 2022Palombella Vito J.Chief Scientific OfficerSale4,463$1.72$7.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35